We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Mgc Pharmaceuticals Limited | LSE:MXC | London | Ordinary Share | AU000000MXC6 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 22.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 4.16M | -20.82M | -0.4749 | -0.80 | 16.66M |
TIDMMXC
RNS Number : 1560U
MGC Pharmaceuticals Limited
31 March 2021
31 March 2021 Results of General Meeting ASX Code: MXC LSE Code: MXC MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company'), would like to confirm the results of the Company's General Meeting held 31 March 2021. All resolutions put to the meeting were passed on a poll. Details of the proxy and poll voting on the resolutions are set out in the attached report. http://www.rns-pdf.londonstockexchange.com/rns/1560U_1-2021-3-31.pdf --Ends-- Authorised for issue by Narelle Warren, Company Secretary, further information, please contact: PR/IR Advisors - Media & MGC Pharmaceuticals Ltd Capital Partners Roby Zomer Rod Hinchcliffe (IR) +61 CEO & Managing Director 412 277 377 +61 8 6382 3390 Rod.Hinchcliffe@mcpartners.com.au info@mgcpharma.com.au UK Broker - Turner Pope UK PR Advisors - Tavistock Andy Thacker Charles Vivian +44 207 920 Andy.Thacker@TurnerPope.com 3150 Zoe Alexander +44 20 3657 Charles.Vivian@tavistock.co.uk 0050 Tim Pearson +44 7983118 Zoe.Alexander@TurnerPope.com 502 Tim.Pearson@tavistock.co.uk
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.
Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.
MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
GMSDKDBQDBKDFNN
(END) Dow Jones Newswires
March 31, 2021 07:54 ET (11:54 GMT)
1 Year Mgc Pharmaceuticals Chart |
1 Month Mgc Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions